Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749601 | 0.90 | TRPV1 (0.41) | TRPV1KLKB1GPR132KIFC1USP30 | |
| SCHEMBL6752290 | 0.90 | CTSL (0.46) | GPR132CTSLHPGDSKIFC1MRGPRX4 | |
| SCHEMBL6752292 | 0.90 | HPGDS (0.37) | CTSLHPGDSMRGPRX4NLRP3LMNA | |
| SCHEMBL6751642 | 0.88 | CTSL (0.45) | CTSLHPGDSNLRP3 | |
| SCHEMBL6747834 | 0.88 | HPGDS (0.44) | CTSLHPGDS | |
| SCHEMBL6749630 | 0.87 | HPGDS (0.39) | CTSLHPGDS | |
| SCHEMBL6985444 | 0.86 | HPGDS (0.39) | CTSLHPGDSNLRP3 | |
| SCHEMBL6749631 | 0.83 | CTSK (0.41) | TRPV1CTSL | |
| SCHEMBL6747703 | 0.83 | CTSL (0.40) | CTSLHPGDS | |
| SCHEMBL6752382 | 0.83 | HPGDS (0.47) | CTSLHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | TRPV1 4447/4885KLKB1 572/4885GPR132 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.